Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose

AIMS: In the PARADIGM‐heart failure trial, sacubitril‐valsartan demonstrated a reduction in heart failure admissions and reduced all‐cause mortality in patients with heart failure with reduced ejection fraction. Although real world data have shown similar benefits regarding efficacy and safety, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Pharithi, Rebabonye B., Ferre‐Vallverdu, Maria, Maisel, Alan S., O'Connell, Eoin, Walshe, Myra, Sweeney, Claire, Barton, James, McDonald, Kathrine, O'Hare, Daniel, Watson, Chris, Gallagher, Joe, Ledwidge, Mark, McDonald, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083433/
https://www.ncbi.nlm.nih.gov/pubmed/31903729
http://dx.doi.org/10.1002/ehf2.12547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083433/
https://www.ncbi.nlm.nih.gov/pubmed/31903729
http://dx.doi.org/10.1002/ehf2.12547

Ejemplares similares